Abstract
In the ARCHER 1050 study, dacomitinib was shown to be more effective than gefitinib in patients with EGFR-mutant NSCLC, especially in patients with the EGFR exon 21L858R mutation. However, adverse events (AEs) were common with the 45 mg initial dose. Currently, real evidence of low-dose dacomitinib activity against the EGFR exon 21 L858R mutation is lacking.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
